This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mushtaq, T. Articles by Farquharson, C. Search for Related Content PubMed PubMed Citation Articles by Mushtaq, T. Articles by Farquharson, C.

Insulin-Like Growth Factor-I Augments Chondrocyte Hypertrophy and Reverses Glucocorticoid-Mediated Growth Retardation in Fetal Mice Metatarsal Cultures

Bone and Endocrine Research Group (T.M., S.F.A.), Royal Hospital for Sick Children, Glasgow G3 8SJ; and Bone Biology Group (T.M., P.B., C.F.), Roslin Institute, Edinburgh EH25 9PS, United Kingdom

Address all correspondence and requests for reprints to: Dr. C. Farquharson, Bone Biology Group, Roslin Institute, Edinburgh EH25 9PS, United Kingdom. E-mail: Colin.Farquharson{at}bbsrc.ac.uk.

The study aims were to improve our understanding of the mechanisms of glucocorticoid-induced growth retardation at the growth plate and determine whether IGF-I could ameliorate the effects. Fetal mouse metatarsals were cultured for up to 10 d with dexamethasone (Dex; 10^–6 M) and/or IGF-I and GH (both at 100 ng/ml). Both continuous and alternate-day Dex treatment inhibited bone growth to a similar degree, whereas IGF-I alone or together with Dex caused an increase in bone growth. GH had no effects. These observations may be explained at the cellular level; cell proliferation within the growing bone was decreased by Dex and increased by IGF-I and these effects were more marked in the cells of the perichondrium than those in the growth plate. However, the most prominent observation was noted in the hypertrophic zone where all treatments containing IGF-I significantly increased (3-fold) the length of this zone, whereas Dex alone had no significant effect. In conclusion, Dex impaired longitudinal growth by inhibiting chondrocyte proliferation, whereas IGF-I stimulated chondrocyte hypertrophy and reversed the growth-inhibitory Dex effects. However, the IGF-I-mediated improvement in growth was at the expense of altering the balance between proliferating and hypertrophic chondrocytes within the metatarsal.

This article has been cited by other articles:

				H. C. Owen, S. J. Roberts, S. F. Ahmed, and C. Farquharson Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1023 - E1034. [Abstract] [Full Text] [PDF]

				T. C. R. Prickett, G. K. Barrell, M. Wellby, T. G. Yandle, A. M. Richards, and E. A. Espiner Response of plasma CNP forms to acute anabolic and catabolic interventions in growing lambs Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1395 - E1400. [Abstract] [Full Text] [PDF]

				V E MacRae, T Burdon, S F Ahmed, and C Farquharson Ceramide inhibition of chondrocyte proliferation and bone growth is IGF-I independent. J. Endocrinol., November 1, 2006; 191(2): 369 - 377. [Abstract] [Full Text] [PDF]

				Y. Wang, S. Nishida, T. Sakata, H. Z. Elalieh, W. Chang, B. P. Halloran, S. B. Doty, and D. D. Bikle Insulin-Like Growth Factor-I Is Essential for Embryonic Bone Development Endocrinology, October 1, 2006; 147(10): 4753 - 4761. [Abstract] [Full Text] [PDF]

				V E MacRae, C Farquharson, and S F Ahmed The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J. Endocrinol., May 1, 2006; 189(2): 319 - 328. [Abstract] [Full Text] [PDF]